GT Biopharma prices USD 7.75 million private placement of Series M preferred, warrants
Bitget2026/09/21 20:11- GT Biopharma expanded a private placement to raise USD 7.75 million through Series M 10% convertible preferred stock and accompanying warrants.
- Amendment increased issuance to 8,611 shares of preferred stock, up from 8,278, with warrants sized to the conversion shares.
- Purchasers received greenshoe rights for up to USD 31.21 million of additional preferred stock purchases, subject to adjustments.
- Transaction structured as an unregistered offering under Rule 506(b) of Regulation D.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Novo Nordisk (NVO.US) Capital Markets Day underwhelms: CEO admits too many commitments, insufficient fulfillment, and the need to rebuild investor confidence
Novo Nordisk CEO Lars Fruergaard Jørgensen said in an interview on Tuesday that the company must make greater efforts to rebuild investor confidence, as its largest drug will face a patent cliff in the early part of the next decade.
BUZZ - Vicor shares surge as royalty income boosts earnings outlook
UBS: Meta’s Muse demonstrates broad application prospects, which will benefit the AI supply chain.
Crypto prices
More
